Article Abstract

Improving clinical outcomes with pembrolizumab in patients with advanced melanoma

Authors: Dae Won Kim, Jonathan S. Zager, Zeynep Eroglu


The discovery of key regulators of T cell response and the development of checkpoint inhibitors have rapidly changed the treatment landscape of metastatic melanoma.


  • There are currently no refbacks.